ArticleEuropean radiology2021
Hepatobiliary phase of gadoxetic acid-enhanced MRI in patients with HCC: prognostic features before resection, ablation, or TACE.
Article in European radiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 23 citations in OpenAlex.
- Beyond Diagnosis: Magnetic Resonance Imaging-Based Imaging Biomarkers for Tumor Biology, Prognosis, and Clinical Decision-Making in Hepatocellular Carcinoma.Korean journal of radiology · 2026Review
- Delta radiomics-based nomogram for preoperative prediction vessels encapsulating tumor clusters (VETC) and prognosis in hepatocellular carcinoma using dynamic contrast-enhanced CT.BMC medical imaging · 2026Article
- Extent of Embolization as an Independent Prognostic Factor in Superselective Conventional Transarterial Chemoembolization for Hepatocellular Carcinoma.Journal of hepatocellular carcinoma · 2026Article
- Prognostic and predictive imaging markers of hepatocellular carcinoma: a pictorial essay.Insights into imaging · 2025Article
- Prediction early recurrence of hepatocellular carcinoma after hepatectomy using gadoxetic acid-enhanced MRI and IVIM.European journal of radiology open · 2025Article
- A novel hybrid model for predicting tertiary lymphoid structures and targeted immunotherapy outcomes in hepatocellular carcinoma: a multicenter retrospective study.European radiology · 2025Article
- MRI Imaging Biomarkers for Prognostication of Hepatocellular Carcinoma.Journal of the Korean Society of Radiology · 2025Review
- Prognostic MRI features to predict postresection survivals for very early to intermediate stage hepatocellular carcinoma.European radiology · 2024Article
- Quantitative information from gadobenate dimeglumine-enhanced MRI can predict proliferative subtype of solitary hepatocellular carcinoma: a multicenter retrospective study.European radiology · 2024Article
- Development and validation of the OSASH score to predict overall survival of hepatocellular carcinoma after surgical resection: a dual-institutional study.European radiology · 2023Article
- Predicting Outcome after Percutaneous Ablation for Early-Stage Hepatocellular Carcinoma Using Various Imaging Modalities.Diagnostics (Basel, Switzerland) · 2023Review
- Imaging prognostication and tumor biology in hepatocellular carcinoma.Journal of liver cancer · 2023Article
- Magnetic resonance imaging for treatment response evaluation and prognostication of hepatocellular carcinoma after thermal ablation.Insights into imaging · 2023Review
- Gadoxetic acid-enhanced MRI with a focus on LI-RADS v2018 imaging features predicts the prognosis after radiofrequency ablation in small hepatocellular carcinoma.Frontiers in oncology · 2023Article
- Role of gadoxetic acid-enhanced liver magnetic resonance imaging in the evaluation of hepatocellular carcinoma after locoregional treatment.World journal of gastroenterology · 2022Review
- Development and validation of a pyradiomics signature to predict initial treatment response and prognosis during transarterial chemoembolization in hepatocellular carcinoma.Frontiers in oncology · 2022Article
- Liver MRI and clinical findings to predict response after drug eluting bead transarterial chemoembolization in hepatocellular carcinoma.Scientific reports · 2021Article
- An excellent nomogram predicts microvascular invasion that cannot independently stratify outcomes of small hepatocellular carcinoma.Annals of translational medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesPatients with hepatocellular carcinoma (HCC) receiving different treatments might have specific prognostic factors that can be captured in the hepatobiliary phase (HBP) of gadoxetic acid-enhanced magnetic resonance imaging (GA-MRI). We aimed to identify the clinical findings and HBP features with prognostic value in patients with HCC.
methodsIn this retrospective, single-institution study, we included patients with Barcelona Clinic Liver Cancer very early/early stage HCC who underwent GA-MRI before treatment. After performing propensity score matching, 183 patients received the following treatments: resection, radiofrequency ablation (RFA), and transarterial chemoembolization (TACE) (n = 61 for each). Cox regression models were used to identify clinical factors and HBP features associated with disease-free survival (DFS) and overall survival (OS).
resultsIn the resection group, large tumor size was associated with poor DFS (hazard ratio [HR] 4.159 per centimeter; 95% confidence interval [CI], 1.669-10.365) and poor OS (HR 8.498 per centimeter; 95% CI, 1.072-67.338). In the RFA group, satellite nodules on HBP images were associated with poor DFS (HR 5.037; 95% CI, 1.061-23.903) and poor OS (HR 9.398; 95% CI, 1.480-59.668). Peritumoral hypointensity on HBP images was also associated with poor OS (HR 13.062; 95% CI, 1.627-104.840). In addition, serum albumin levels and the prothrombin time-international normalized ratio were associated with DFS and/or OS. Finally, in the TACE group, no variables were associated with DFS/OS.
conclusionsDifferent HBP features and clinical factors were associated with DFS/OS among patients with HCC receiving different treatments. KEY POINTS: • In patients who underwent resection for HCC, a large tumor size on HBP images was associated with poor disease-free survival and overall survival. • In the RFA group, satellite nodules and peritumoral hypointensity on HBP images, along with decreased serum albumin levels and PT-INR, were associated with poor disease-free survival and/or overall survival. • In the TACE group, no clinical or HBP imaging features were associated with disease-free survival or overall survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.